Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.66 |
| ▸ | TOP2A | P11388 | 2/20 | 0.66 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.66 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.64 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673590 | 0.90 | GSK3B (0.69) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9089522 | 0.90 | GSK3B (0.63) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL8111016 | 0.90 | TOP2A (0.58) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9689537 | 0.90 | GSK3B (0.68) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL1345769 | 0.89 | GSK3B (0.70) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL14143619 | 0.89 | GSK3B (0.61) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL13581380 | 0.88 | GSK3B (0.60) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL9688213 | 0.86 | GSK3B (0.64) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL5236368 | 0.86 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB | |
| SCHEMBL501142 | 0.86 | GSK3B (0.50) | GSK3BTOP2ATOP2BCACNA1FPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1666477-B1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-8106072-B2 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | ASAHINA YOSHIKAZU | 2009-07-09 | — | — | US | disclosed |
| US-7514451-B2 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| EP-1666477-A1 | 7-(4-SUBSTITUTED 3- CYCLOPROPYLAMINOMETHYL-1- PYRROLIDINYL) Q UINOLONECARBOXYLIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0911328-B1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2006-02-08 | — | — | EP | disclosed |
| US-6825353-B2 | AN AMINE SUBSTITUENT AT THE 7-POSITION OF THE QUINOLONE-CARBOXYLIC ACID DERIVATIVE IS PRODUCED; BACTERICIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1304329-A2 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| US-6184388-B1 | ANTIBACTERIAL AND ANTIMICROBIAL, QUINOLINE ANTIBIOTIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-02-06 | — | — | US | disclosed |
| US-6121285-A | 5-AMINO-7-(4-(1-AMINOCYCLOPROPYL-3-FLUORO-1-PYRROLIDINYL)-6 -FLUORO-1-(2-FLUORO-1-CYCLOPROPYL)-1,4-DIHYDRO-8-METHOXY-4-OXOQUINOLINE-3 -CARBOXYLIC ACID, FOR EXAMPLE; ANTIMICROBIAL DRUGS WITH HIGH SAFETY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0911328-A1 | SUBSTITUTED AMINOCYCLOALKYLPYRROLIDINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| US-5859026-A | ADMINISTERING AS AN ANTIBACTERIAL AGENT | HOKURIKU SEIYAKU CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| US-5849757-A | Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
| EP-0806421-A1 | QUINOLINECARBOXYLIC ACID DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 1997-11-12 | — | — | EP | disclosed |
| EP-0641793-B1 | 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | HOKURIKU PHARMACEUTICAL (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5547962-A | QUINOLONE ANTIBIOTICS | HORURIKU SEIYAKU CO., LTD. (JP) | 1996-08-20 | — | — | US | disclosed |
| EP-0641793-A1 | 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176824-A1 | 7- (4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl) quinolonecarboxylic acid derivative technical field | CLPP, PRSS1, FOSB | GSK3B 4103/4885TOP2A 138/4885TOP2B 219/4885 |
| US-20060281779-A1 | 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative | RPS27L, RPS7, RPSA | GSK3B 4399/4885TOP2A 171/4885TOP2B 308/4885 |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | NQO2, QPCT, QARS1 | GSK3B 1080/4885TOP2A 747/4885TOP2B 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.